Sudeep Pharma Ltd

Sudeep Pharma Ltd

₹ 699 2.89%
12 Dec - close price
About

Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.[1]

Key Points

Company Overview[1]
Sudeep Pharma Limited is a leading manufacturer of excipients and specialty ingredients catering to the pharmaceutical, food, and nutrition industries. The company has evolved from producing basic excipients to offering a broad portfolio of over 100 products, serving more than 1,100 customers globally. Its mineral-based ingredients, including calcium, zinc, iron, and magnesium salts, are widely used in formulations across health, nutrition, and food applications.

  • Market Cap 7,892 Cr.
  • Current Price 699
  • High / Low 796 / 631
  • Stock P/E 56.9
  • Book Value
  • Dividend Yield 0.00 %
  • ROCE 35.6 %
  • ROE 32.8 %
  • Face Value 1.00

Pros

  • Company has delivered good profit growth of 50.4% CAGR over last 5 years

Cons

  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Operating Profit
OPM %
Interest
Depreciation
Profit before tax
Tax %
EPS in Rs
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2024 Mar 2025
123 215 343 459 502
98 171 276 277 311
Operating Profit 25 44 67 182 191
OPM % 21% 20% 20% 40% 38%
3 3 7 6 9
Interest 1 1 2 5 7
Depreciation 3 4 5 9 11
Profit before tax 25 43 69 175 183
Tax % 27% 22% 27% 24% 24%
18 33 50 133 139
EPS in Rs 128.02 236.60 356.04 945.36 14.27
Dividend Payout % 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 32%
3 Years: 14%
TTM: 9%
Compounded Profit Growth
10 Years: %
5 Years: 50%
3 Years: 40%
TTM: 4%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 33%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2024 Mar 2025
Equity Capital 1 1 1 1 10
Reserves 80 113 162 355 481
20 31 84 78 140
30 67 97 80 86
Total Liabilities 131 213 344 514 717
60 68 137 180 189
CWIP 8 24 8 45 88
Investments 6 19 0 0 0
57 102 199 289 439
Total Assets 131 213 344 514 717

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2024 Mar 2025
10 35 -3 66 49
-22 -40 -38 -49 -79
12 13 51 -13 53
Net Cash Flow -0 8 10 4 23

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2024 Mar 2025
Debtor Days 90 94 114 115 135
Inventory Days 77 79 104 150 309
Days Payable 70 79 76 115 145
Cash Conversion Cycle 97 93 142 151 298
Working Capital Days 46 13 30 99 144
ROCE % 36% 36% 36%

Shareholding Pattern

Numbers in percentages

14 Recently
Nov 2025
76.16%
1.54%
14.76%
7.54%
No. of Shareholders 2,17,982

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents